DM

Dethardt Muller

Chief Technology Officer

Abalos Therapeutics GmbH

Vienna, Vienna


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Abalos Therapeutics GmbH
Industry
research
Employees
24.0
Seniority
C suite
Annual Revenue
5000000.0
Total Funding
50827830.0
Latest Funding
Series A

Technologies

Outlook Microsoft Office 365 Typekit Bootstrap Framework WordPress.org Mobile Friendly Vimeo Nginx Google Font API reCAPTCHA

Keywords

biotechnology research anti-cancer immunotherapy innate immune response adaptive immune response arenavirus therapy tumor microenvironment immune evasion t cell activation tumor antigen presentation cancer treatment immunostimulatory approach systemic administration tumor regression metastasis control immune cell influx drug candidates clinical trials preclinical studies cgmp manufacturing targeted therapy immune activation novel therapeutics payload-carrying therapeutics cancer immunotherapy tumor cells immune system engagement oncolytic therapy safety profile distant metastases specific cancer indications solid tumors virotherapy cancer pipeline infectious agents antigen-presenting cells t cell infiltration immune surveillance persistent inflammation r&d funding medical need biomedicine viral infection immuno-oncology drug development scientific research clinical evaluation healthcare innovation health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans